An abstract of a presentation at the November 2022 meeting of the Society for Neuro-Oncology entitled “Early signal of activity from a phase 2 study of ST101, a first-in-class peptide antagonist of CCAAT/enhancer-binding proteinβ (C/EBPβ), in recurrent glioblastoma (GBM)“ provided the first glimpse of the outcome for GBM [208]. The gene discussed is CEBPB; the disease is glioblastoma.